Dual GIP / GLP-1 Receptor Agonist
Buy Tirzepatide 60mg
FDA-approved dual agonist (Mounjaro/Zepbound) with the strongest clinical evidence of any anti-obesity compound before Retatrutide. 72-week trials, −22.5% body weight.
≥98% Purity
HPLC Verified
Research Grade
Lyophilized
Fast Shipping
Free $200+
Specifications
Mechanism of Action
GIP Receptor Agonism
Tirzepatide was the first approved dual GIP/GLP-1 agonist. GIP receptor activation enhances insulin secretion in a glucose-dependent manner and improves insulin sensitivity in adipose and muscle tissue. Counterintuitively, GIP agonism (not antagonism) proved synergistic with GLP-1 in driving weight loss — a finding that challenged earlier hypotheses.
GLP-1 Receptor Agonism
GLP-1 activation reduces appetite via hypothalamic pathways, slows gastric emptying (increasing satiety), and potentiates insulin secretion. Tirzepatide's GLP-1 component is structurally biased compared to native GLP-1, producing a different receptor activation profile than semaglutide.
Adipose Tissue Remodeling
Tirzepatide selectively reduces visceral fat — the metabolically dangerous fat depot — more than subcutaneous fat. Phase 3 sub-studies using MRI showed preferential visceral adipose reduction, which correlates with improvements in insulin resistance, liver health, and cardiovascular risk markers.
Research Findings
SURMOUNT-1 Phase 3 Trial
2,539 participants, 72 weeks. Maximum dose (15mg/week) achieved −22.5% body weight vs −2.5% placebo. 91% of participants achieved ≥5% weight loss; 57% achieved ≥20% weight loss. The most robust obesity trial data at time of publication.
Jastreboff et al., New England Journal of Medicine (2022)
SURMOUNT-2 (Type 2 Diabetes)
938 participants with T2D. Maximum dose achieved −15.7% body weight and HbA1c reduction of −2.58% — superior to all comparator compounds including semaglutide 1mg.
Garvey et al., Lancet (2022)
SURMOUNT-4 (Weight Regain Prevention)
Following 36 weeks of open-label tirzepatide, participants were randomized to continue or switch to placebo. Continuation group maintained −25.8% total weight loss; placebo group regained 14% — establishing the importance of continued treatment.
Aronne et al., JAMA (2024)
Cardiovascular: SURMOUNT-MMO
Tirzepatide significantly reduced cardiovascular events in people with obesity and established heart disease — the first obesity drug to demonstrate CV outcomes benefit alongside semaglutide (SELECT trial).
Lilly SURMOUNT-MMO readout (2025)
Preclinical Safety Data
Tirzepatide has the most extensive human safety dataset of any compound in this product category — approved by FDA with comprehensive Phase 3 data from >5,000 participants. Primary safety concerns are GI-related. Thyroid C-cell carcinoma risk (observed in rodent GLP-1 studies) has not been confirmed in human trials. Pancreatitis risk is theoretical and not significantly elevated in trial data.
Research Dosing Protocols
From published literature — for research reference only.
Standard Weekly Injection
2.5–15 mg/week
Once weekly
FDA-approved dosing: start 2.5mg/week, increase by 2.5mg every 4 weeks to 5mg, 10mg, 15mg maintenance. Subcutaneous injection — abdomen, thigh, or upper arm.
Accelerated Titration
5–15 mg/week
Once weekly
Research protocols sometimes use faster escalation (2-week steps). Higher GI side effect burden. Not recommended for initial users.
Reconstitution Guide
- 1
Allow vial to reach room temperature before opening.
- 2
Draw 1–2 mL bacteriostatic water into a syringe.
- 3
Inject BAC water slowly down the inner wall of the vial.
- 4
Gently swirl to dissolve — never shake.
- 5
15mg vial + 1.5mL BAC water = 10mg/mL. For a 10mg dose, draw 1.0mL.
- 6
Store at 4°C after reconstitution. Use within 4 weeks.
Stacking Guide
BPC-157
GI side effects are the main tolerability concern with tirzepatide. BPC-157 protects the GI mucosa and reduces intestinal inflammation — potentially improving tolerability during dose escalation.
GHK-Cu
$50.00Rapid fat loss can reduce skin elasticity. GHK-Cu stimulates collagen and elastin synthesis topically, supporting skin quality during aggressive body recomposition protocols.
Frequently Asked Questions
What is Tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. It is FDA-approved as Mounjaro (for type 2 diabetes, 2022) and Zepbound (for obesity, 2023). In Phase 3 trials, the 15mg dose achieved −22.5% body weight over 72 weeks — the most effective approved anti-obesity medication.
How does Tirzepatide compare to Semaglutide?
Head-to-head trial (SURMOUNT-5, 2025) showed tirzepatide 15mg achieved −20.2% weight loss vs −13.7% for semaglutide 2.4mg over 72 weeks — approximately 47% greater weight loss. Tirzepatide also showed superior improvements in waist circumference and cardiometabolic markers.
What is the difference between Tirzepatide and Retatrutide?
Tirzepatide is a GIP/GLP-1 dual agonist. Retatrutide adds glucagon receptor agonism (triple agonist), which increases energy expenditure through hepatic metabolism. Phase 3 data shows retatrutide achieving −28.7% vs tirzepatide's −22.5% — approximately 28% more weight loss.
What are the common side effects?
GI effects are most common: nausea (25–45%), diarrhea (20–30%), vomiting (10–20%), constipation. These are dose-dependent and typically peak during dose escalation. Most patients report significant improvement after 4–8 weeks at a stable dose.
How is research-grade Tirzepatide stored?
Lyophilized: −20°C, stable for 24 months. After reconstitution with bacteriostatic water: store at 4°C, use within 4 weeks. Keep away from light. Do not freeze reconstituted solution.
Research Disclosure: All products on this page are for laboratory research purposes only. They are not FDA-approved for human consumption, injection, or therapeutic use. Research findings cited are from preclinical and clinical studies and should not be interpreted as medical advice. Always consult a licensed healthcare provider.
Related Products
BPC-157 + TB-500 Blend 20mg
Buy BPC-157 + TB-500 Blend 20mg online — research-grade lyophilized peptide for laboratory use. Body Protection Compound-157 (15-amino-acid pentadecapeptide). ≥98% HPLC purity verified.
CAS: 137525-51-0
Tirzepatide 60mg
$399.99